From GlobeNewswire:

Tim Kelly has been appointed as the chief technology officer at Caribou Biosciences, Inc. He brings over 25 years of experience in clinical and commercial product development, manufacturing, and supply chain operations. Mr. Kelly will lead the company’s technical operations strategy and execution. Caribou plans to report initial dose expansion data from the ANTLER trial and share the recommended Phase 2 dose (RP2D) for CB-010 in Q2 2024. The company also plans to initiate a Phase 3 pivotal trial evaluating CB-010 in second-line LBCL by year-end 2024. Additionally, Caribou will present a corporate update at the 42nd Annual J.P. Morgan Healthcare Conference on Thursday, January 11, 2024 at 11:15 am PST.



Read more: Caribou Biosciences Appoints Tim Kelly as Chief Technology